| NCT ID | NCT02754856 |
| Title | Tremelimumab (Anti-CTLA-4) Plus MEDI4736 (Anti-PD-L1) in Resectable Colorectal Cancer Liver Metastases. |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | M.D. Anderson Cancer Center |
| Indications | |
| Therapies |
Bevacizumab + Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin + Tremelimumab |
| Age Groups: | adult |